Spun out of Sunol Molecular in 2002 and itself acquired by NantCell in June 2017, Altor BioScience is a biopharmaceutical company developing a new class of therapeutic products (immunotherapeutic agents) for the treatment of cancer, viral infections and autoimmune diseases. The firm offers STAR Fusion Reagents for diagnosing and targeting cancer and viral infections; and STAR Multimer Reagents for research and design of anti-cancer and anti-viral vaccine. Products in clinical stage include a monoclonal antibody that prevents and treats staphylococcal infections in premature neonates; and STAR-Ck or ALT-801, an anti-cancer drug. It also has products in various development stages, such as fusion agents for cancer and viral infections, immunotherapeutics against staphylococcal infections, gene therapy for cancer, and multimers reagents. In addition, the company provides products for detecting novel disease targets. Its products are used in the direct and quantitative detection of endogenous peptide antigens' presentation on diseased cells and tissues. Altor's drug discovery and therapeutic approaches are based on its integrated technologies for single-chain T-cell receptors and single-chain major histocompatibility complex molecules. Altor's patented technologies facilitate the production of soluble TCR and major histocompatibility complex molecules. The resulting product candidates bind novel targets on virus-infected or cancerous cells that are not recognized by therapeutic antibodies. Altor is employing these technologies to improve the safety and efficacy of existing therapeutics.
